Drug Trial Radar · NCT07949695
Neoadjuvant Trastuzumab Rezetecan Plus Toripalimab and Endocrine Therapy in HR-Positive HER2-Low Breast Cancer
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Nov 1, 2026
Primary completion
May 31, 2028
Study completion May 31, 2029
Sponsor
- Lead sponsor
- Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, prospective exploratory clinical study. The purpose of this study is to evaluate the efficacy and safety of trastuzumab rezetecan (SHR-A1811) combined with toripalimab and endocrine therapy as neoadjuvant treatment for patients with stage II-III HR-positive, HER2-low primary breast cancer. Eligible participants will receive the combination neoadjuvant regimen before surgery. The primary endpoint is pathological complete response (pCR, ypT0/is ypN0) rate after surgery. Secondary endpoints include objective response rate (ORR), residual cancer burden (RCB), event-free survival (EFS), overall survival (OS), and safety. A total of 30 participants will be enrolled. The recruitment period will last for 12 months. All enrolled subjects will receive study treatment and follow-up according to the study protocol.
Conditions
- HR Positive/HER2 Low Breast Cancer
- Neoadjuvant Therapy
- SHR-A1811
- Toripalimab
Interventions
trastuzumab rezetecan (SHR-A1811) Toripalima、Endocrine therapy(ET)Drug
Patients receive 6 cycles of neoadjuvant trastuzumab rezetecan (4.8 mg/kg IV Q3W) plus toripalimab (240 mg IV Q3W) plus daily endocrine therapy (SERM/AI ± OFS; OFS for pre/perimenopausal women), followed by surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pathological Complete Response Rate (pCR, ypT0/isN0)Time frame: At surgery (after completion of 6 cycles of neoadjuvant treatment, each cycle is 21 days).
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tianjin Medical University Cancer Institute and Hospital
Tianjin, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.